Post-earnings recap
Reported
Thu, Nov 6, 2025
EPS actual
$1.27
EPS est.
$1.12
EPS surprise
+13.60%
1-day move
+32.31%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Haemonetics Corp's strong EPS performance, exceeding expectations by 13.60%, led to a significant stock increase of 32.31%. The positive reaction reflects investor confidence in the company's operational execution and future potential. However, the lack of revenue data and guidance leaves some uncertainty about the overall financial outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.27 | N/A | +13.60% |
Management expressed satisfaction with the quarter's performance, highlighting operational strengths and a commitment to innovation. They emphasized their ongoing efforts to enhance product offerings.
We are pleased with our performance this quarter, demonstrating strong operational execution.
Our focus on innovation continues to drive positive results.